Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Heart disease has surpassed cancer as the leading cause of death among Hispanics/Latinos in the U.S. However, cancer remains a major health concern, accounting for approximately 17% of deaths. Through public education, community resources, and improved access to care, survival rates continue to improve.
Breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer death among Hispanic/Latina women. Additionally, cervical cancer rates continue to pose a serious threat to Latinas. In the fall 2024, The Latino Cancer Institute hosted a Virtual Friday Forum Series, bringing together leading voices in the field to discuss the latest research findings and promising interventions.
Lung cancer continues to be the leading cause of cancer death among Hispanic/Latino men. While smoking rates are lower among Latinos compared to other groups, targeted prevention efforts and early detection remain critical.
The Latino Cancer Institute is committed to reducing the burden of cancer in Latino communities through advocacy, research, and community-driven solutions. Learn more about us.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
There are currently no upcoming events.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
An international team has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin. Scientists report that exposure to colibactin in early childhood imprints a distinct genetic signature on the DNA of colon cells -- one that may increase the risk of developing colorectal cancer before the age of 50.
Hyperbaric oxygen treatment provides long-term relief for patients suffering from late radiation-induced injuries after treatment of cancer in the lower abdominal area. Five years after hyperbaric oxygen therapy, the positive effects remain.
Researchers have discovered a previously unknown type of connective tissue cells that surround cancer cells in pancreatic tumors. The newly discovered cells counteract tumor development and may therefore be a target for research into new treatments for pancreatic cancer, which is one of the deadliest forms of cancer.
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk of dying from their cancer compared to similar patients who were not taking statins, according to a new study.
One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ's dense tissue to define the margins between malignant and normal tissue. A new study uses DNA origami structures to selectively deliver fluorescent imaging agents to pancreatic cancer cells without affecting normal cells. The study, led by mechanical science and engineering professors found that specially engineered DNA origami structures carrying imaging dye packets can specifically target human KRAS mutant cancer cells, which are present in 95% of pancreatic cancer cases.
Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.
